Literature DB >> 19860001

High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia.

Alessandro Antonelli1, Clodoveo Ferri, Silvia-Martina Ferrari, Fabio Galetta, Ferdinando Franzoni, Gino Santoro, Salvatore De Marco, Emiliano Ghiri, Poupak Fallahi.   

Abstract

AIM: To evaluate serum levels of N-terminal pro-brain natriuretic peptide (NTproBNP) and tumor necrosis factor alpha (TNF-alpha) in a large series of patients with hepatitis C associated with mixed cryoglobulinemia (MC+HCV).
METHODS: Serum NTproBNP and TNF-alpha levels were assayed in 50 patients with MC+HCV, and in 50 sex- and age-matched controls.
RESULTS: Cryoglobulinemic patients showed significantly higher mean NTproBNP and TNF-alpha levels than controls (P < 0.001; Mann-Whitney U test). By defining high NTproBNP level as a value higher than 125 pg/mL (the single cut-off point for outpatients under 75 years of age), 30% of MC+HCV and 6% of controls had high NTproBNP (c2, P < 0.01). With a cut-off point of 300 pg/mL (used to rule out heart failure (HF) in patients under 75 years of age), 8% of MC+HCV and 0 controls had high NTproBNP (c2, P < 0.04). With a cut-off point of 900 pg/mL (used for ruling in HF in patients aged 50-75 years; such as the patients of our study), 6% of MC+HCV and 0 controls had high NTproBNP (c2, P = 0.08).
CONCLUSION: The study demonstrates high levels of circulating NTproBNP and TNF-alpha in MC+HCV patients. The increase of NTproBNP may indicate the presence of a subclinical cardiac dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860001      PMCID: PMC2768887          DOI: 10.3748/wjg.15.5074

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

Authors:  R W Troughton; C M Frampton; T G Yandle; E A Espiner; M G Nicholls; A M Richards
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

3.  Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure.

Authors:  Wendy Johnson; Torbjørn Omland; Christian Hall; Caroline Lucas; Ole L Myking; Caroline Collins; Marc Pfeffer; Jean-Lucien Rouleau; Lynne W Stevenson
Journal:  J Am Coll Cardiol       Date:  2002-05-15       Impact factor: 24.094

4.  Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

Authors:  Roberto Latini; Serge Masson; Inder Anand; Dianne Judd; Aldo P Maggioni; Yann-Tong Chiang; Maurizio Bevilacqua; Monica Salio; Paola Cardano; Peter H J M Dunselman; Nicolaas J Holwerda; Gianni Tognoni; Jay N Cohn
Journal:  Circulation       Date:  2002-11-05       Impact factor: 29.690

5.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.

Authors:  D R Murdoch; T A McDonagh; J Byrne; L Blue; R Farmer; J J Morton; H J Dargie
Journal:  Am Heart J       Date:  1999-12       Impact factor: 4.749

6.  Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea.

Authors:  L Cabanes; B Richaud-Thiriez; Y Fulla; F Heloire; C Vuillemard; S Weber; D Dusser
Journal:  Chest       Date:  2001-12       Impact factor: 9.410

7.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.

Authors:  J Koglin; S Pehlivanli; M Schwaiblmair; M Vogeser; P Cremer; W vonScheidt
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

8.  Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population.

Authors:  M Nakamura; H Endo; M Nasu; N Arakawa; T Segawa; K Hiramori
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

9.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.

Authors:  L Katherine Morrison; Alex Harrison; Padma Krishnaswamy; Radmila Kazanegra; Paul Clopton; Alan Maisel
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

10.  Association between hepatitis C virus core protein and carotid atherosclerosis.

Authors:  Yuko Ishizaka; Nobukazu Ishizaka; Eiko Takahashi; Tadao Unuma; Ei-ichi Tooda; Hideki Hashimoto; Ryozo Nagai; Minoru Yamakado
Journal:  Circ J       Date:  2003-01       Impact factor: 2.993

View more
  1 in total

Review 1.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.